These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21689063)

  • 1. Combination therapy with naltrexone and bupropion for obesity.
    Billes SK; Greenway FL
    Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Padwal R
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
    Smith SR; Fujioka K; Gupta AK; Billes SK; Burns C; Kim D; Dunayevich E; Greenway FL
    Diabetes Obes Metab; 2013 Sep; 15(9):863-6. PubMed ID: 23489381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
    Billes SK; Sinnayah P; Cowley MA
    Pharmacol Res; 2014 Jun; 84():1-11. PubMed ID: 24754973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naltrexone for the treatment of obesity: review and update.
    Lee MW; Fujioka K
    Expert Opin Pharmacother; 2009 Aug; 10(11):1841-5. PubMed ID: 19537999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update.
    Christou GA; Kiortsis DN
    Hormones (Athens); 2015; 14(3):370-5. PubMed ID: 26188223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New obesity pill: new hopes, old fears.
    Lancet; 2010 Dec; 376(9758):2042. PubMed ID: 21168038
    [No Abstract]   [Full Text] [Related]  

  • 11. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF; Shukla AP; Aronne LJ
    Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
    Wilcox CS; Oskooilar N; Erickson JS; Billes SK; Katz BB; Tollefson G; Dunayevich E
    Addict Behav; 2010 Mar; 35(3):229-34. PubMed ID: 19926400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Greig SL; Keating GM
    Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
    Katsiki N; Hatzitolios AI; Mikhailidis DP
    Ann Med; 2011 Jun; 43(4):249-58. PubMed ID: 21254901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of a combination medication for the treatment of obesity.
    Greenway FL; Whitehouse MJ; Guttadauria M; Anderson JW; Atkinson RL; Fujioka K; Gadde KM; Gupta AK; O'Neil P; Schumacher D; Smith D; Dunayevich E; Tollefson GD; Weber E; Cowley MA
    Obesity (Silver Spring); 2009 Jan; 17(1):30-9. PubMed ID: 18997675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample.
    Dalton M; Finlayson G; Walsh B; Halseth AE; Duarte C; Blundell JE
    Int J Obes (Lond); 2017 Aug; 41(8):1232-1236. PubMed ID: 28373674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.